Clinical Trials on Levodopa Induced Dyskinesias (LID) in Norway

Total 6 results

Neurocrine Biosciences

Completed

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia

United States
Neurocrine Biosciences

Completed

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia (TD)

United States, Puerto Rico
Neurocrine Biosciences

Completed

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Tardive Dyskinesia (TD)

United States, Puerto Rico
Neurocrine Biosciences

Completed

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia

3

Subscribe